Evrenzo self attestation

Are you a Healthcare Professional?

This site is intended only for Healthcare Professionals, particularly those who are experienced in the management of anaemia associated with chronic kidney disease.

Information for patients

The website you have tried to access contains clinical information designed specifically for medical professionals experienced in treating this condition. If you have any questions about your health or treatment, please consult your doctor.

 

Astellas
evrenzo leavingsoon

You are leaving the website

You are now leaving an Astellas Pharma Ltd. website.
Astellas bears no responsibility for the content of any 3rd party material
nor how it might be used. Click OK to proceed.

Image of man on mountain top painting a chair
Image of man on mountain top painting a chair
EVRENZOTM▼ for patients with anaemia of CKD

EVRENZO (roxadustat) is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD)1

Image of woman on mountain top playing guitar
Image of woman on mountain top playing guitar
A first-in-class HIF-PH inhibitor2 that mimics the body’s natural response to hypoxia3

EVRENZO (roxadustat) is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD)1

Introducing EVRENZO™ –

can change the clinical management of anaemia of CKD

EVRENZO (roxadustat) is the first HIF-PH inhibitor to have gained approval for the treatment of symptomatic anaemia associated with CKD. It mimics the body's physiological response to hypoxia3 by increasing production of erythropoietin and improving iron availability, thereby increasing haemoglobin levels and increasing red blood cell production with a reduced use of intravenous iron.1 EVRENZO is a tablet taken 3 times a week. We invite you to explore this website to discover the difference EVRENZO can make for your patients.

  1. EVRENZO SmPC.
  2. Sanghani NS, Haase VH. Adv Chronic Kidney Dis. 2019;26(4):253-266.
  3. Del Vecchio L, Locatelli F. Expert Opin Investig Drugs. 2018;27(1):125-133.
image

Any

questions?

See for yourself

Patients and specialists share their experiences

  • Professor Jon Barratt on the disease burden

  • How does it feel to live with anaemia of CKD?

  • Professor Sunil Bhandari on the challenges of management

Tell me more

Tell Me More

I would like to receive:

*Mandatory fields

*) I hereby consent that Astellas Pharma Nordic** can use the personal details I have provided for the purpose of sending me healthcare, medical and scientific-related information and materials, including invitations*** for Astellas events and activities by email, which Astellas believes may be of value to me, relevant to my work or tailored to my professional profile and may be promotional in nature.

IMPORTANT: Your consent is voluntary and you can withdraw it at any time by clicking the “unsubscribe” link in any email communication you receive from Astellas going forward, by sending an email to privacy@astellas.com.

Astellas is committed to protecting your personal information and will only use it in accordance with the applicable data privacy law and our Astellas Privacy Notice. For further information on how we process and protect your personal information and how you may exercise your data protection rights, please refer to our Privacy Notice at https://policy.astellas.dk/se-privacy-notice-hcp/.

If you have any questions or concerns, please contact us at privacy@astellas.com.

**) For the purpose of this consent, “Astellas Pharma Nordic” shall mean Astellas Pharma a/s (Denmark), Astellas Pharma AB (Sweden), Astellas Pharma (Norway) and Astellas Pharma A/S, filial i Finland (Finland).

***) Astellas complies with applicable industry requirements, and will not send any invitations directly to any hospital-employed HCPs where not allowed.

News and events

Coming soon ......

Reporting Adverse Events

▼ Detta läkemedel är föremål för utökad övervakning. Detta kommer att göra det möjligt att snabbt identifiera ny säkerhetsinformation. Hälso- och sjukvårdspersonal uppmanas att rapportera varje misstänkt biverkning.

CKD, chronic kidney disease; DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; HIF-PH, hypoxia-inducible factor prolyl-hydroxylase; NDD, non-dialysis-dependent.

 

EVRENZO™ (roxadustat), 20, 50, 70, 100 och 150 mg filmdragerade tabletter, B03XA05, Rx (särskilt läkemedel), F

▼Detta läkemedel är föremål för utökad övervakning.

Indikationen är behandling av vuxna patienter med symtomatisk anemi associerad med kronisk njursjukdom (CKD). Kontraindikationer är överkänslighet mot den aktiva substansen, jordnötter, soja eller hjälpämne, användning under graviditetens tredje trimester samt amning. Varningar och försiktighet inkluderar risk för allvarliga (inklusive dödliga) kardiovaskulära och trombovaskulära händelser, krampanfall och allvarliga infektioner inklusive sepsis. Ska inte sättas in hos kvinnor som planerar att bli gravida eller under graviditet. Fertila kvinnor måste använda en högeffektiv preventivmetod under behandling och i minst en vecka efter sista dosen. Försiktighet gällande administrering krävs vid måttligt nedsatt leverfunktion och rekommenderas inte vid kraftigt nedsatt leverfunktion. Felanvändning kan leda till en överdrivet förhöjd hematokrit vilket kan leda till livshotande komplikationer i hjärt-kärlsystemet.

Astellas Pharma AB, Box 21046, 200 21 Malmö. Produktresumé 2024-09. 

För ytterligare information och förpackningar se www.fass.se.